^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    surovatamig (AZD0486)

    i
    Other names: AZD0486, TNB-486, AZD-0486
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    CD3 agonist, CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=276, Recruiting, AstraZeneca | Trial completion date: Apr 2031 --> Feb 2028 | Trial primary completion date: Apr 2031 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    2ms
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    2ms
    ASSURO: Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    surovatamig (AZD0486)
    3ms
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=276, Recruiting, AstraZeneca | N=180 --> 276
    Enrollment change
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    3ms
    SYRUS: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (clinicaltrials.gov)
    P1/2, N=142, Recruiting, AstraZeneca | Trial primary completion date: Jul 2026 --> Nov 2026
    Trial primary completion date
    |
    surovatamig (AZD0486)
    7ms
    SOUNDTRACK-F1: A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (clinicaltrials.gov)
    P3, N=1015, Recruiting, AstraZeneca | Trial completion date: Feb 2035 --> Nov 2031 | Trial primary completion date: Apr 2031 --> Nov 2031
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    7ms
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=317, Recruiting, AstraZeneca | N=231 --> 317 | Trial completion date: Jan 2027 --> Apr 2028 | Trial primary completion date: Jan 2027 --> Apr 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    10ms
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=180, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Jan 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    1year
    AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    surovatamig (AZD0486)
    1year
    D7400C00006: A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=231, Recruiting, AstraZeneca | N=116 --> 231
    Enrollment change
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    1year
    AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (clinicaltrials.gov)
    P1/2, N=120, Recruiting, AstraZeneca | Trial completion date: Feb 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    surovatamig (AZD0486)
    1year
    Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma (ASH 2024)
    Median prior lines of therapy was 3 (range 2–12), 18 (38%) pts received prior lenalidomide–based therapy, 7 (15%) pts received prior chimeric antigen receptor T-cell therapy (CAR-T), and 4 (9%) received prior CD20 TCE therapy. The exposure-response analysis supports the target dose of 7.2 mg. Further studies of AZD0486 are planned as monotherapy and in combination regimens.
    Clinical • Minimal residual disease
    |
    CD20 negative
    |
    Foresight CLARITY™
    |
    lenalidomide • surovatamig (AZD0486)